1. The thioredoxin system and cancer therapy: a review

   • Fariba Mohammadi
   • Arash Soltani
   • Seyed Isaac Hashemy

   Review Article 31 July 2019 Pages: 925 - 935

   

2. Prodrugs as drug delivery system in oncology

   • J. Delahousse
   • C. Skarbek
   • A. Paci

   Review Article 07 August 2019 Pages: 937 - 958

   

3. Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review

   • Inthuorn Kulma
   • Kanyarat Boonprasert
   • Kesara Na-Bangchang

   Review Article 04 September 2019 Pages: 959 - 975

   

4. Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients

   • Silpa Nuthalapati
   • Sven Stodtmann
   • Hao Xiong

   Original Article 29 August 2019 Pages: 977 - 986

   

5. Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma

   • Yuto Yamada
   • Yuta Ohno
   • Akio Suzuki

   Original Article 03 September 2019 Pages: 987 - 992

   

6. Population pharmacokinetics of siltuximab: impact of disease state

   • Mina Nikanjam
   • Jin Yang
   • Edmund V. Capparelli

   Original Article 03 September 2019 Pages: 993 - 1001

   

7. Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

   • Ivelina Gueorguieva
   • Josep Tabernero
   • Karim A. Benhadji

   Original Article 03 September 2019 Pages: 1003 - 1015

   

8. Evaluation of the potential for QTc prolongation with avelumab

   • Yulia Vugmeyster
   • Gülseren Güzel
   • Haiqing Dai

   Original Article Open access 03 September 2019 Pages: 1017 - 1026

   

9. Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma

   • K. Yamazaki
   • T. Doi
   • A. Ohtsu

   Original Article 03 September 2019 Pages: 1027 - 1037

   

10. Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab

    • Baoquan Liu
    • Fei Su
    • Jianguo Zhang

    Original Article 04 September 2019 Pages: 1039 - 1049

    

11. Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan

    • Mayu Yunokawa
    • Shinsuke Sasada
    • Kenji Tamura

    Original Article 04 September 2019 Pages: 1051 - 1058

    

12. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer

    • Midori Shimada
    • Hiroyuki Yamaguchi
    • Hiroshi Mukae

    Original Article 05 September 2019 Pages: 1059 - 1064

    

13. A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients

    • Tetsuo Tani
    • Katsuhiko Naoki
    • Kenzo Soejima

    Original Article 06 September 2019 Pages: 1065 - 1071

    

14. Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice

    • Jim H. Hughes
    • Richard N. Upton
    • David J. R. Foster

    Original Article 06 September 2019 Pages: 1073 - 1087

    

15. Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer

    • Gerardo Rosati
    • Raffaele Addeo
    • Salvatore Bianco

    Original Article 06 September 2019 Pages: 1089 - 1096

    

16. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases

    • Kazuyo Shimada
    • Shiori Hasegawa
    • Mitsuhiro Nakamura

    Original Article 09 September 2019 Pages: 1097 - 1105

    

17. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study

    • Takumi Sakurada
    • Sanako Bando
    • Keisuke Ishizawa

    Original Article 09 September 2019 Pages: 1107 - 1114

    

18. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer

    • Saichun Qi
    • Ya Mao
    • Mingjun Jiang

    Original Article 09 September 2019 Pages: 1115 - 1123

    

19. Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects

    • Kiana Keyvanjah
    • Blaire Cooke
    • Alvin Wong

    Original Article 11 September 2019 Pages: 1125 - 1132

    

20. Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment

    • Yanan Sun
    • Lingyan Yan
    • Rong Jia

    Original Article 12 September 2019 Pages: 1133 - 1143

    

21. A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies

    • Filipa Lynce
    • Hongkun Wang
    • Michael J. Pishvaian

    Clinical Trial Report 19 September 2019 Pages: 1145 - 1151